HCW Biologics Inc. Received NASDAQ Staff Determination Letter
23 déc. 2024 08h10 HE
|
HCW Biologics, Inc
Mandatory press release to disclose receipt of Nasdaq Staff Determination Letter.
HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate
18 nov. 2024 07h00 HE
|
HCW Biologics, Inc
HCW Biologics signed license agreement with WY Biotech
HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights
14 nov. 2024 16h40 HE
|
HCW Biologics, Inc
Press release for Q3 2024 business highlights and financial results
HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights
15 mai 2024 16h39 HE
|
HCW Biologics, Inc
Earning release for Q1 2024
HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights
01 avr. 2024 16h10 HE
|
HCW Biologics, Inc
Q4 and Year End Earnings Release and Business Highlights
HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders
14 juin 2023 07h30 HE
|
HCW Biologics, Inc
MIRAMAR, Fla., June 14, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCW Biologics” or the “Company”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and...